GZPHF: AI 评分 43/100 — AI 分析 (4月 2026)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a Chinese pharmaceutical company involved in the research, development, manufacture, and sale of medicines and healthcare products. The company operates through four segments and has a network of retail pharmacy outlets.
Key Facts:
AI Score: 43/100
Sector: Healthcare
公司概况
概要：
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a Chinese pharmaceutical company involved in the research, development, manufacture, and sale of medicines and healthcare products. The company operates through four segments and has a network of retail pharmacy outlets.
Guangzhou Baiyunshan Pharmaceutical Holdings operates in the specialty and generic drug manufacturing sector, focusing on both traditional Chinese medicine and Western medicine. With a diverse portfolio spanning pharmaceuticals, healthcare products, and retail pharmacies, the company leverages its established presence in the Chinese market and international reach to drive growth.
GZPHF是做什么的？
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, established in 1997 and based in Guangzhou, China, is a comprehensive pharmaceutical company engaged in the research, development, manufacture, and sale of a wide range of pharmaceutical products. These include Chinese patent medicines, Western medicines, chemical raw materials, natural and biological medicines, and intermediates. The company operates through four key segments: Great Southern TCM, focusing on traditional Chinese medicine; Great Commerce, handling wholesale and retail operations; Great Health, concentrating on healthcare products and services; and Others, encompassing investments and other business activities.
Guangzhou Baiyunshan has expanded its operations to include the wholesale, retail, import, and export of medicines and medical equipment. It also produces beverages, food, healthcare products, and various pharmaceutical formulations. The company has a significant retail presence, operating 154 retail chain pharmacy outlets as of December 31, 2021, under brands like Cai Zhi Lin, Jian Min, and GPC Prescription Pharmacy. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013.
GZPHF的投资论点是什么？
Guangzhou Baiyunshan Pharmaceutical Holdings presents a mixed investment case. The company's diverse product portfolio and established retail network in China provide a stable revenue base, reflected in its $5.93 billion market cap and a dividend yield of 3.13%. However, a relatively low profit margin of 3.9% and gross margin of 16.6% indicate potential challenges in operational efficiency and pricing power. The company's low beta of 0.29 suggests lower volatility compared to the broader market. Upcoming growth catalysts include expansion of its healthcare services and product lines. Investors should closely monitor the company's ability to improve profitability and navigate regulatory changes in the Chinese pharmaceutical market.
GZPHF在哪个行业运营？
Guangzhou Baiyunshan operates in the competitive pharmaceutical industry, facing both domestic and international players. The Chinese pharmaceutical market is experiencing growth driven by an aging population and increasing healthcare spending. The company's focus on both traditional Chinese medicine and Western medicine allows it to cater to a broad consumer base. Competitors include DNPUF (Daiichi Sankyo), HKMPF (China Resources Pharmaceutical Group), HKMPY (Sinopharm Group), HLBBF (LG Chem), and HLUBF (Yuhan).
Drug Manufacturers - Specialty & Generic
Healthcare
GZPHF有哪些增长机遇？
- Expansion of Healthcare Services: Guangzhou Baiyunshan's investment in healthcare services, including medical care, health management, and elderly care, represents a significant growth opportunity. As China's population ages, the demand for these services is expected to increase substantially. The company can leverage its existing infrastructure and expertise to capture a larger share of this market, potentially increasing revenue by 15-20% over the next three years.
- New Product Development and Innovation: Investing in research and development to create new pharmaceutical products and healthcare solutions can drive future growth. Focusing on innovative treatments and therapies can differentiate Guangzhou Baiyunshan from its competitors and attract new customers. Successful development and commercialization of new products could lead to a 10-15% increase in revenue within five years.
- Geographic Expansion: Expanding its retail pharmacy network and distribution channels to new regions within China and internationally can significantly increase Guangzhou Baiyunshan's market reach. Targeting underserved markets and establishing strategic partnerships can accelerate this expansion. This expansion could contribute to a 10% annual revenue growth over the next five years.
- Strategic Acquisitions and Partnerships: Acquiring smaller pharmaceutical companies or forming strategic partnerships with other industry players can provide access to new technologies, products, and markets. These acquisitions can enhance Guangzhou Baiyunshan's competitive position and drive synergistic growth. Successful integration of acquired companies could boost overall revenue by 8-12% within three years.
- Digital Transformation and E-commerce: Investing in digital technologies and expanding its e-commerce presence can improve operational efficiency, enhance customer engagement, and drive online sales. Developing a user-friendly online platform and leveraging data analytics can personalize customer experiences and optimize marketing efforts. This digital transformation could lead to a 10% increase in online sales within two years.
- Market Cap of $5.93 billion indicates a substantial presence in the pharmaceutical market.
- P/E ratio of 13.94 suggests a potentially undervalued stock compared to industry peers.
- Dividend Yield of 3.13% offers an attractive income stream for investors.
- Gross Margin of 16.6% reflects the company's profitability after accounting for the cost of goods sold.
- Beta of 0.29 indicates lower volatility compared to the broader market, potentially making it a more stable investment.
GZPHF提供哪些产品和服务？
- Researches and develops Chinese patent and Western medicines.
- Manufactures and sells chemical raw materials and biological medicines.
- Engages in the wholesale and retail of Western and Chinese medicines.
- Imports and exports medicines and medical apparatus.
- Produces beverages, food, and healthcare products.
- Invests in health industry, such as medical care and elderly care.
- Provides commercial and advertising services.
GZPHF如何赚钱？
- Develops, manufactures, and sells pharmaceutical products.
- Operates a network of retail pharmacy outlets.
- Provides healthcare services and invests in health-related industries.
- Generates revenue through product sales, retail operations, and service fees.
- Patients and consumers seeking pharmaceutical products and healthcare services.
- Hospitals and medical institutions.
- Retail pharmacies and distributors.
- Healthcare providers and professionals.
- Established brand reputation in the Chinese pharmaceutical market.
- Extensive retail pharmacy network.
- Diverse product portfolio spanning traditional Chinese medicine and Western medicine.
- Vertical integration across the pharmaceutical value chain.
什么因素可能推动GZPHF股价上涨？
- Upcoming: Expansion of healthcare services targeting the aging population in China.
- Upcoming: Development and launch of new pharmaceutical products and therapies.
- Ongoing: Increasing market penetration in existing geographic regions.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market reach.
GZPHF的主要风险是什么？
- Potential: Increasing competition from domestic and international pharmaceutical companies.
- Potential: Regulatory changes impacting drug pricing and market access in China.
- Potential: Patent expirations and generic competition.
- Ongoing: Economic slowdown in China affecting consumer spending on healthcare products.
GZPHF的核心优势是什么？
- Diverse product portfolio including both Chinese and Western medicines.
- Extensive retail pharmacy network across China.
- Established brand reputation and market presence.
- Integrated operations across the pharmaceutical value chain.
GZPHF的劣势是什么？
- Relatively low profit margin compared to industry peers (3.9%).
- Dependence on the Chinese market.
- Limited international presence compared to global pharmaceutical companies.
- Potential vulnerability to regulatory changes in the pharmaceutical industry.
GZPHF有哪些机遇？
- Expanding healthcare services to capitalize on the aging population.
- Developing new and innovative pharmaceutical products.
- Increasing its presence in the international market.
- Leveraging digital technologies to enhance customer engagement and operational efficiency.
GZPHF面临哪些威胁？
- Increasing competition from domestic and international pharmaceutical companies.
- Potential regulatory changes impacting drug pricing and market access.
- Patent expirations and generic competition.
- Economic slowdown in China affecting consumer spending on healthcare products.
GZPHF的竞争对手是谁？
- Daiichi Sankyo — Global pharmaceutical company with a focus on innovative medicines. — (DNPUF)
- China Resources Pharmaceutical Group — One of the largest pharmaceutical groups in China. — (HKMPF)
- Sinopharm Group — Leading pharmaceutical and healthcare conglomerate in China. — (HKMPY)
- LG Chem — South Korean chemical company with a pharmaceutical division. — (HLBBF)
- Yuhan — South Korean pharmaceutical company focused on ethical drugs and consumer healthcare products. — (HLUBF)
Key Metrics
- MoonshotScore: 43/100
Company Profile
- CEO: Hong Li
- Headquarters: Guangzhou, CN
- Employees: 28,138
- Founded: 2010
AI Insight
AI analysis pending for GZPHF
- OTC Tier: OTC Other
- Disclosure Status: Unknown
常见问题
What does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited do?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a comprehensive pharmaceutical company that researches, develops, manufactures, and sells a wide range of pharmaceutical products, including traditional Chinese medicines and Western medicines. It operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. The company also operates a network of retail pharmacy outlets and invests in healthcare services, such as medical care and elderly care, providing commercial and advertising services.
What do analysts say about GZPHF stock?
AI analysis for GZPHF is currently pending. Without analyst consensus, key valuation metrics, and growth considerations are unavailable. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Factors to consider include the company's financial performance, competitive landscape, and regulatory environment.
What are the main risks for GZPHF?
The main risks for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited include increasing competition from domestic and international pharmaceutical companies, potential regulatory changes impacting drug pricing and market access in China, patent expirations and generic competition, and the impact of an economic slowdown in China on consumer spending on healthcare products. Additionally, as an OTC-listed company, GZPHF faces risks related to limited disclosure, low liquidity, and regulatory scrutiny.